Neurovalens

Neurovalens operates at the intersection of medical devices, digital therapeutics, neuroscience and non-invasive brain stimulation. Its portfolio spans insomnia, anxiety, weight management and PTSD, giving it a broader condition footprint than a single-indication device company. The main differentiation is the Modius platform’s use of electrical vestibular system stimulation through electrodes positioned behind the ears, delivered in wearable, home-use products rather than through pharmaceuticals or clinic-bound procedures. Modius Sleep has FDA 510(k) clearance for chronic insomnia, Modius Calm has FDA clearance for anxiety, Modius Lean has received FDA authorization for weight management, and Modius Spero received FDA De Novo approval for PTSD in 2026. Relative to broader neurostimulation and digital mental-health companies, Neurovalens distinguishes itself through physician-prescribed devices, condition-specific waveforms, regulatory progress across multiple indications and access through the Department of Veterans Affairs. Its Belfast base and estimated employee band of one to ten indicate a relatively small operating footprint compared with larger medical-device incumbents, making regulatory execution and commercialization partnerships particularly important to its competitive position.

Neurovalens shows a transition from early-stage financing and product development toward regulated commercialization. Founded in 2013, the company completed equity crowdfunding in 2017, two Series A financings in 2019 and 2020 totaling more than $12.5 million, and additional venture, grant and assistance funding through 2022 and 2024. The August 2025 financing event added $6.7 million in venture capital and $1.35 million in debt financing, with Clarendon Fund Managers, Investment Fund for Northern Ireland and Whiterock Finance associated with the transaction. Product and regulatory milestones accelerated thereafter. Modius Lean entered the U.S. market after FDA De Novo approval in December 2025, while Modius Sleep achieved EU and UK approvals in March 2026. Modius Spero’s FDA De Novo approval on May 26, 2026 created a new PTSD indication and supported a veterans-focused U.S. rollout. The appointment of Kate Willis as Vice President of Commercialization in June 2024 suggests an intentional shift toward market access, while reported hiring activity indicates continued team building. The trajectory is therefore defined less by headcount scale than by expanding indications, regulatory approvals, clinical evidence and institutional distribution channels.